|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/10/13 Heron Therapeutics, Inc./DE 10-Q 3/31/13 45:1.7M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 164K
2: EX-10.AI Material Contract HTML 81K
3: EX-10.AJ Material Contract HTML 84K
4: EX-10.AK Material Contract HTML 81K
5: EX-31.1 Certification -- §302 - SOA'02 HTML 21K
6: EX-31.2 Certification -- §302 - SOA'02 HTML 20K
7: EX-32.1 Certification -- §906 - SOA'02 HTML 15K
8: EX-32.2 Certification -- §906 - SOA'02 HTML 16K
28: R1 Document and Entity Information HTML 41K
21: R2 Condensed Balance Sheets HTML 69K
26: R3 Condensed Statements of Operations (Unaudited) HTML 56K
30: R4 Condensed Statements of Cash Flows (Unaudited) HTML 87K
41: R5 Business and Basis of Presentation HTML 25K
22: R6 Cash Equivalents HTML 21K
25: R7 Fair Value Measurements HTML 26K
20: R8 Net Loss Per Share HTML 22K
16: R9 Stock-Based Compensation HTML 29K
42: R10 Comprehensive Loss HTML 21K
32: R11 Discontinued Operations HTML 27K
31: R12 Convertible Notes to Related Parties HTML 25K
36: R13 Stockholders' Equity HTML 36K
37: R14 Subsequent Event HTML 17K
35: R15 Business and Basis of Presentation (Policies) HTML 37K
38: R16 Net Loss Per Share (Tables) HTML 20K
27: R17 Stock-Based Compensation (Tables) HTML 31K
29: R18 Discontinued Operations (Tables) HTML 19K
34: R19 NET LOSS PER SHARE - Outstanding potentially HTML 24K
dilutive options, warrants and convertible notes
(Details)
45: R20 STOCK-BASED COMPENSATION - Stock-based HTML 31K
compensation expense (Details)
39: R21 STOCK-BASED COMPENSATION - Stock option activity HTML 44K
(Details)
23: R22 DISCONTINUED OPERATIONS - Loss from discontinued HTML 15K
operations (Details)
33: R23 Business and Basis of Presentation (Details HTML 35K
Narrative)
24: R24 Stock-Based Compensation (Details Narrative) HTML 19K
15: R25 Comprehensive Loss (Details Narrative) HTML 20K
40: R26 Discontinued Operations (Details Narrative) HTML 21K
43: R27 Convertible Notes to Related Parties (Details HTML 76K
Narrative)
18: R28 Stockholders' Equity (Details Narrative) HTML 60K
44: XML IDEA XML File -- Filing Summary XML 56K
17: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 155K
9: EX-101.INS XBRL Instance -- appa-20130331 XML 241K
11: EX-101.CAL XBRL Calculations -- appa-20130331_cal XML 71K
12: EX-101.DEF XBRL Definitions -- appa-20130331_def XML 143K
13: EX-101.LAB XBRL Labels -- appa-20130331_lab XML 306K
14: EX-101.PRE XBRL Presentations -- appa-20130331_pre XML 261K
10: EX-101.SCH XBRL Schema -- appa-20130331 XSD 70K
19: ZIP XBRL Zipped Folder -- 0001193125-13-213597-xbrl Zip 44K
| EX-31.2 |
Exhibit 31.2
SECTION 302 CERTIFICATIONS
I, John B. Whelan, Chief Financial Officer, certify that:
| 1. | I have reviewed this quarterly report on Form 10-Q of A.P. Pharma, Inc.; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others, particularly during the period in which this report is being prepared; |
| b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and |
| d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
| a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
| b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
| Date: May 10, 2013 |
| /s/ John B. Whelan |
| John B. Whelan |
| Chief Financial Officer |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 5/10/13 | 8-K | ||
| For Period end: | 3/31/13 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/12/24 Heron Therapeutics, Inc./DE 10-K 12/31/23 72:10M Donnelley … Solutions/FA 3/29/23 Heron Therapeutics, Inc./DE 10-K 12/31/22 73:12M Donnelley … Solutions/FA 2/28/22 Heron Therapeutics, Inc./DE 10-K 12/31/21 74:12M ActiveDisclosure/FA 2/24/21 Heron Therapeutics, Inc./DE 10-K 12/31/20 74:12M ActiveDisclosure/FA |